Skip to content
OpenCapital
Get started

Haemonetics HAE Cash & Equivalents

Cash & Equivalents at other companies

Abbott logo
AbbottABT
$6.8B+4.1%
TFX
TeleflexTFX
$329.55M+16.8%
Boston Scientific logo
Boston ScientificBSX
$850M+146%
Medtronic logo
MedtronicMDT
$1.95B-12.1%
LivaNova logo
LivaNovaLIVN
$539.71M-26.9%
ICU Medical logo
ICU MedicalICUI
$288.33M-0.5%

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.37B-18.0%
Enterprise value$4.4B-12.5%
P/S2.5×-0.5×

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's cash & equivalents?
Haemonetics (HAE) reported cash & equivalents of $245.44M in Q1 2026.
How has Haemonetics's cash & equivalents changed year-over-year?
Haemonetics's cash & equivalents decreased by 20.0% year-over-year, from $306.76M to $245.44M.
What is the long-term trend for Haemonetics's cash & equivalents?
Over 5 years (2021 to 2026), Haemonetics's cash & equivalents has grown at a 5.0% compound annual growth rate (CAGR), from $192.31M to $245.44M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.